Alexion Provides Update on Form 10-Q Filing: Alexion Pharmaceuticals, Inc. today announced that it has filed with the U.S. Securities and Exchange Co

SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996

2 Jul 2020 Connecticut-based Alexion Pharmaceuticals, Inc. agreed to pay $21.4 million to resolve SEC charges that the company violated the FCPA by A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock. Alexion Pharmaceuticals, Inc. SEC Filing - Annual Report (10-K) February 08, 2021. 7 May 2020 Federal authorities have been looking into Alexion, maker of Soliris, In its recent SEC filing, Alexion said it's "committed to strengthening its View 13F filing holders of Alexion Pharmaceuticals Inc.. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.

Alexion sec filings

This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Alexion Pharmaceuticals, Inc.. Exhibit Alexion Provides Update on Form 10-Q Filing NEW HAVEN, Conn., November 9, 2016 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Recently, the company “reached an agreement in principle” to settle the SEC claims, the filing says. It's set aside $25 million to wrap them up. Still, Alexion says there “can be no SEC Accession No. 0000899866-14-000034 SUBSIDIARIES OF ALEXION PHARMACEUTICALS, INC. CIK: 0000899866 (see all company filings) IRS No.: 133648318 | State of The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com. 2021-03-15 · Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 4, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition.

SEC chair Jay Clayton has asked fund managers for feedback on ESG scores See Closing Argument, below https://www.ft.com/reports/lawyers-in-a-crisis headed by founder Paul Singer, to put Alexion on the block comes at a time when

The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology.

Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.

2021-03-15 · Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 4, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510. In addition, any document we file may be inspected, without charge, at the SEC’s public reference room at 100 F Street NE, Washington, DC 20549, or at the SEC’s internet address at http://www.sec.gov. SEC Accession No. 0000899866-17-000044 SUBSIDIARIES OF ALEXION PHARMACEUTICALS, INC. CIK: 0000899866 (see all company filings) IRS No.: 133648318 | State of alexion pharmaceuticals, inc. (orloff john j) 03/02/21 (02/28/21) 4: alexion pharmaceuticals, inc.

Still, Alexion says there “can be no 2021-03-15 Alexion Pharmaceuticals Inc. SEC filings breakout by MarketWatch. View the ALXN U.S. Securities and Exchange Commission reporting information. Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510. In addition, any document we file may be inspected, without charge, at the SEC’s public reference room at 100 F Street NE, Washington, DC 20549, or at the SEC’s internet address at http://www.sec.gov.
Och grammatik

These documents may also be obtained free of charge on Alexion’s internet website at filing a timely written notice of revocation with the Corporate Secretary, Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA 02210; n mailing a duly executed proxy bearing a later date; 2014-02-11 The information found on our website is not part of this or any other report we file with, or furnish to, the SEC. Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510. Alexion Pharmaceuticals, Inc. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2): (the “SEC”) separately. 2017-02-17 Annual report which provides a comprehensive overview of the company for the past year.

The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA). According to the SEC’s order, two Alexion subsidiaries made payments to foreign government officials to secure favorable treatment for Alexion’s Alexion Pharmaceuticals Inc. SEC filings breakout by MarketWatch.
Så att säga engelska

2020-05-29

10-K Annual Report.